

TABLE OF CONTENTS

SCHEMA.....	5
1. OBJECTIVES.....	8
1.1 Primary Objectives.....	8
1.2 Secondary Objectives.....	8
2. BACKGROUND.....	8
2.1 Study Disease(s).....	8
2.2 CTEP and/or CIP IND Agent(s).....	8
2.3 Other Agent(s).....	9
2.4 Rationale.....	9
2.5 Correlative Studies Background.....	9
3. PATIENT SELECTION.....	9
3.1 Eligibility Criteria.....	9
3.2 Exclusion Criteria.....	11
3.3 Inclusion of Women and Minorities.....	12
4. REGISTRATION PROCEDURES.....	13
4.1 Investigator and Research Associate Registration with CTEP.....	13
4.2 Site Registration.....	14
4.3 Patient Registration.....	16
4.4 General Guidelines.....	18
5. TREATMENT AND/OR IMAGING PLAN.....	19
5.1 Agent Administration.....	19
5.2 For phase 1 protocols only: Definition of Dose-Limiting Toxicity.....	22
5.3 Dose Expansion Cohorts:.....	23
5.4 General Concomitant Medication and Supportive Care Guidelines.....	23
5.5 Duration of Therapy.....	24
5.6 Duration of Follow Up.....	24
6. DOSING DELAYS/DOSE MODIFICATIONS.....	25
7. ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS.....	27
7.1 Comprehensive Adverse Events and Potential Risks List(s) (CAEPRs).....	27
7.2 Adverse Event Characteristics.....	29
7.3 Expedited Adverse Event Reporting.....	29
7.4 Routine Adverse Event Reporting.....	35
7.5 Secondary Malignancy.....	35
7.6 Second Malignancy.....	35
8. PHARMACEUTICAL and/or IMAGING AGENT INFORMATION.....	35
8.1 CTEP and/or CIP IND Agent(s).....	36

NCI Protocol #:

Version Date:

8.2	<i>Other Investigational Agent(s)</i>	38
8.3	<i>Commercial Agent(s)</i>	38
9.	BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES	39
9.1	Integral Laboratory or Imaging Studies.....	41
9.2	Investigational Device Information	41
9.3	Integrated Correlative Studies.....	42
9.4	Exploratory/Ancillary Correlative Studies	42
9.5	Special Studies	42
10.	STUDY CALENDAR	43
11.	MEASUREMENT OF EFFECT.....	44
11.1	Antitumor Effect – Solid Tumors	44
11.2	Antitumor Effect – Hematologic Tumors	51
11.3	Other Response Parameters	51
12.	STUDY OVERSIGHT AND DATA REPORTING / REGULATORY REQUIREMENTS.....	51
12.1	Study Oversight	51
12.2	Data Reporting.....	52
12.3	CTEP Multicenter Guidelines.....	55
12.4	Collaborative Agreements Language.....	56
12.5	Genomic Data Sharing Plan.....	58
13.	STATISTICAL CONSIDERATIONS.....	58
13.1	Study Design/Endpoints.....	58
13.2	Sample Size/Accrual Rate.....	59
13.3	Stratification Factors.....	60
13.4	Analysis of Secondary Endpoints	60
13.5	<i>For phase 2 protocols only: Reporting and Exclusions</i>	60
	REFERENCES	62
APPENDIX A	PERFORMANCE STATUS CRITERIA	63
APPENDIX B	CTEP MULTICENTER GUIDELINES.....	64
APPENDIX C	PATIENT DRUG INFORMATION HANDOUT AND WALLET CARD	66
APPENDIX D	BIOASSAY TEMPLATES	69